Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China.

ABSTRACT:

Background

Patients treated with immunotherapy in the real-world may have significantly different responses to those meeting inclusion criteria for random controlled clinical studies. There is a partial overlap in approved indications for the use of the different immune checkpoint inhibitors (ICIs) currently available. A comprehensive assessment of the efficacy, safety and economic effects of various ICIs is a problem that clinicians need to address.

Methods

Analyzed real-world data was collected from non-small cell lung cancer (NSCLC) patients who were treated with ICIs from hospitalized patients in the Lung Cancer Center of Peking Union Medical College Hospital between 2018 and 2021. The objectives were to evaluate the efficacy and safety of different ICIs for the treatmen

SUBMITTER: Miao K 

PROVIDER: S-EPMC8982065 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature